(Q36429699)

14 August 2017

1 reference

title

Drug interactions during therapy with three major groups of antimicrobial agents (English)

1 reference

14 August 2017

Kasra Shakeri-Nejad

1

1 reference

14 August 2017

Ralf Stahlmann

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

639-651

1 reference

Epidemiology of drug-drug interactions as a cause of hospital admissions

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Human cytochromes P450: problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Macrolide antibacterials. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Macrolide drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

A potentially hazardous interaction between erythromycin and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Comparative safety of the different macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Potential interaction between telithromycin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Profile of moxifloxacin drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Quinolone binding to DNA is mediated by magnesium ions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Voriconazole does not affect the steady‐state pharmacokinetics of digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Systemic antifungal agents. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Drug interactions of the newer oral antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Clinical pharmacokinetics of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Optimisation of itraconazole therapy using target drug concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Interactions between tacrolimus and antimicrobial agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Does inhibition of P-glycoprotein lead to drug-drug interactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Update on drug interactions with azole antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Voriconazole potentiates warfarin‐induced prothrombin time prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.639

21 January 2018

Identifiers

DOI

10.1517/14656566.7.6.639

1 reference

14 August 2017

1 reference